Rezidivierende CD30-positive kutane lymphoproliferative Erkrankung

Zusammenfassung

Die CD30-positiven primär kutanen lymphoproliferativen Erkrankungen stellen nach der Mycosis fungoides die zweithäufigste Form der kutanen T-Zell-Lymphome dar. Diese Gruppe umfasst die lymphomatoide Papulose (LyP), das primär kutane anaplastische großzellige Lymphom (pcALCL) und Borderline-Läsionen.

Therapeutisch findet bei lokalisierten Läsionen eine topische oder intraläsionale Steroidgabe Anwendung.

Bei disseminiertem Befund kommen u.a. Methotrexat, PUVA oder Brentuximab-Vedotin therapeutisch in Betracht.

Wir stellen hier eine 60-jährige Patientin vor, deren Klinik die Heterogenität dieser Erkrankungen und einen wechselhaften Verlauf über nahezu 3 Jahre zeigt.

Abstract

The CD30-positive primary cutaneous lymphoproliferative diseases represent the second most common form of cutaneous T-cell lymphoma after mycosis fungoides. This group comprises lymphomatoid papulosis (LyP), primary cutaneous anaplastic large cell lymphoma (pcALCL), and borderline lesions. Topical or intralesional steroid administration is used therapeutically for localized lesions. In the case of disseminated disease, therapeutic options include methotrexate, PUVA or brentuximab vedotin.

Here, we present a 60-year old female whose clinical presentation shows the heterogeneity of these diseases and an undulating course over almost three years.

Publication History

Article published online:
18 April 2024

• Literatur

• 1 Dippel E, Assaf C, Becker JC. et al. S2k-Guidelines – Cutaneous lymphomas (ICD10 C82 – C86): Update 2021. J Dtsch Dermatol Ges 2022; 20: 537-554 DOI: 10.1111/ddg.14706. (PMID: 35446497)
• 2 Stoll JR, Willner J, Oh Y. et al. Primary cutaneous T-cell lymphomas other than mycosis fungoides and Sézary syndrome. Part I: Clinical and histologic features and diagnosis. J Am Acad Dermatol 2021; 85: 1073-1090
• 3 Booken N, Goerdt S, Klemke CD. Clinical spectrum of primary cutaneous CD30-positive anaplastic large cell lymphoma: an analysis of the Mannheim Cutaneous Lymphoma Registry. J Dtsch Dermatol Ges 2012; 10: 331-339 DOI: 10.1111/j.1610-0387.2011.07794.x. (PMID: 22525148)
• 4 Willemze R, Jaffe ES, Burg G. et al. WHO-EORTC classification for cutaneous lymphomas. Blood 2005; 105: 3768-3785 DOI: 10.1182/blood-2004-09-3502. (PMID: 15692063)
• 5 Miquel J, Fraitag S, Hamel-Teillac D. et al. Lymphomatoid papulosis in children: a series of 25 cases. Br J Dermatol 2014; 171: 1138-1146 DOI: 10.1111/bjd.13061. (PMID: 24749749)
• 6 Kiniwa Y, Ide Y, Fukushima M. et al. A case of systemic anaplastic large cell lymphoma with ‘Hodgkin-like’ appearance and skin involvement mimicking lymphomatoid papulosis. J Cutan Pathol 2011; 38: 38-42
• 7 Prince HM, Kim YH, Horwitz SM. et al. ALCANZA study group. Brentuximab vedotin or physicianʼs choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. Lancet 2017; 390: 555-566 DOI: 10.1016/S0140-6736(17)31266-7. (PMID: 28600132)
• 8 Horwitz SM, Scarisbrick JJ, Dummer R. et al. Randomized phase 3 ALCANZA study of brentuximab vedotin vs physicianʼs choice in cutaneous T-cell lymphoma: final data. Blood Adv 2021; 5: 5098-5106 DOI: 10.1182/bloodadvances.2021004710. (PMID: 34507350)
• 9 Pileri A, Guglielmo A, Patrizi A. et al. Erythroderma with brentuximab vedotin (skin side effects in mycosis fungoides). J Dtsch Dermatol Ges 2021; 19: 99-102
• 10 Gosmann J, Stadler R. Long term survival, time to next treatment and CD30 expression in patients with advanced CD30⁺ cutaneous T-cell lymphoma treated with Brentuximab vedotin – A monocentric retrospective analysis of twelve patients. J Dtsch Dermatol Ges 2022; 20: 514-518 DOI: 10.1111/ddg.14675. (PMID: 35319153)
• 11 Lewis DJ, Talpur R, Huen AO. et al. Brentuximab Vedotin for Patients With Refractory Lymphomatoid Papulosis: An Analysis of Phase 2 Results. JAMA Dermatol 2017; 153: 1302-1306